166 related articles for article (PubMed ID: 7894139)
41. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
[TBL] [Abstract][Full Text] [Related]
42. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis.
Oh BK; Kim YJ; Park YN; Choi J; Kim KS; Park C
Am J Gastroenterol; 2006 Apr; 101(4):831-8. PubMed ID: 16494581
[TBL] [Abstract][Full Text] [Related]
43. C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms.
Vlasoff DM; Baschinsky DY; De Young BR; Morrison CD; Nuovo GJ; Frankel WL
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):237-41. PubMed ID: 12373150
[TBL] [Abstract][Full Text] [Related]
44. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.
Nakatsukasa H; Ashida K; Higashi T; Ohguchi S; Tsuboi S; Hino N; Nouso K; Urabe Y; Kinugasa N; Yoshida K; Uematsu S; Ishizaki M; Kobayashi Y; Tsuji T
Hepatology; 1996 Jul; 24(1):82-8. PubMed ID: 8707287
[TBL] [Abstract][Full Text] [Related]
45. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver.
Brunt EM; Swanson PE
Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S53-61. PubMed ID: 1374219
[TBL] [Abstract][Full Text] [Related]
46. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas.
Visakorpi T; Kallioniemi OP; Koivula T; Harvey J; Isola J
Mod Pathol; 1992 Nov; 5(6):643-8. PubMed ID: 1369801
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical study of p53, EGF, EGF-receptor, v-erb B and ras p21 in squamous cell carcinoma of hypopharynx.
Otsu M; Hayashi Y; Amatsu M; Itoh H
Kobe J Med Sci; 1994 Dec; 40(5-6):139-53. PubMed ID: 7616733
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemistry of hepatocellular carcinoma associated with cirrhosis.
Espinoza CG; Pillarisetti SG; Azar HA
Ann Clin Lab Sci; 1984; 14(6):467-73. PubMed ID: 6210034
[TBL] [Abstract][Full Text] [Related]
49. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues.
Tiniakos D; Spandidos DA; Kakkanas A; Pintzas A; Pollice L; Tiniakos G
Anticancer Res; 1989; 9(3):715-21. PubMed ID: 2548435
[TBL] [Abstract][Full Text] [Related]
50. TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
El Bassuoni MA; Talaat RM; Ibrahim AA; Shaker OT
Egypt J Immunol; 2008; 15(1):39-50. PubMed ID: 20306668
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical study of the appearance of some markers in liver adjoining hepatocellular carcinoma.
Cantaboni A; Sironi M; Taccagni GL; Ferrari AM
Basic Appl Histochem; 1986; 30(2):165-72. PubMed ID: 2427060
[TBL] [Abstract][Full Text] [Related]
52. Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study.
Torp SH; Gulati S; Johannessen E; Dalen A
J Exp Clin Cancer Res; 2007 Sep; 26(3):353-9. PubMed ID: 17987795
[TBL] [Abstract][Full Text] [Related]
53. Transforming growth factor α immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue.
Pannain VL; Morais JR; Damasceno-Ribeiro O; Avancini-Alves V
Ann Hepatol; 2012; 11(4):495-9. PubMed ID: 22700631
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.
Felipe-Silva A; Wakamatsu A; Dos Santos Cirqueira C; Alves VA
World J Gastroenterol; 2016 Jul; 22(27):6246-56. PubMed ID: 27468214
[TBL] [Abstract][Full Text] [Related]
55. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma.
Liu X; Jiang W; Aucejo F; Kim R; Miller C; Byrne M; Lopez R; Yerian L
Hum Pathol; 2011 Jun; 42(6):882-91. PubMed ID: 21292299
[TBL] [Abstract][Full Text] [Related]
56. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
Karabork A; Kaygusuz G; Ekinci C
Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
[TBL] [Abstract][Full Text] [Related]
57. Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-induced hepatocarcinogenesis.
Badawy AA; El-Hindawi A; Hammam O; Moussa M; Gabal S; Said N
APMIS; 2015 Oct; 123(10):823-31. PubMed ID: 26279457
[TBL] [Abstract][Full Text] [Related]
58. Immunohistochemical correlation of epidermal growth factor receptor and c-erbB-2 with histopathologic grading of mucoepidermoid carcinoma.
Khiavi MM; Vosoughhosseini S; Saravani S; Halimi M
J Cancer Res Ther; 2012; 8(4):586-90. PubMed ID: 23361279
[TBL] [Abstract][Full Text] [Related]
59. [A clinico-pathological study involving a consecutive series of 75 primary liver carcinomas with resection].
Haratake J; Horie A; Takeda S; Hisatomi K; Tokudome S
Gan No Rinsho; 1988 May; 34(6):759-63. PubMed ID: 2837593
[TBL] [Abstract][Full Text] [Related]
60. [A clinicopathological study of 108 consecutive primary hepatic malignancies in the University of Occupational and Environmental Health].
Haratake J; Horie A; Taoka Y; Okuno F; Takeda S; Sato H
Gan No Rinsho; 1987 Oct; 33(13):1689-93. PubMed ID: 2447304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
